Sacituzumab Govitecan and Bevacizumab for NSCLC Brain Metastases
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorMaastricht University Medical Center
About this trial
This study will evaluate whether the combination of sacituzumab govitecan (SG) and bevacizumab will result in shrinkage of brain metastases from patients with non-squamous non-small cell lung cancer (NSCLC), with disease progression on chemotherapy and immunotherapy.
Eligibility criteria
Qualifiers
Signed informed consent must be obtained prior to participation in the study.
Participant is an adult ≥ 18 years of age at the time of informed consent.
ECOG performance status ≤1.
Estimated life expectancy of 12 weeks or more.
Disqualifiers
Leptomeningeal metastasis (based on MRI or CSF cytology, if strong suspicion despite negative MRI, CSF analysis should be done).
Previous treatment with TROP2 inhibitor or angiogenesis inhibitor.
Known hypersensitivity to the study drugs, its metabolites, or formulation excipient.
Positive serum pregnancy test or women who are breastfeeding.
Trial design
Treatments tested in this trial
- Sacituzumab Govitecan-Hziy 180 MG plus bevacizumab
Treatment groups
25 Participants
are divided into 1 treatment groupSponsors and collaborators
Maastricht University Medical Center
Lead sponsor
Gilead Sciences
Collaborator
Source ClinicalTrials.gov